Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
Holding GB:GSK?
Track your performance easily
GSK Stock Chart & Stats
Day’s Range― - ―
52-Week Range1,282.50p - 1,823.50p
Previous CloseN/A
Volume367.08K
Average Volume (3M)7.04M
Market Cap
£55.03B
Enterprise Value74.17B
Total Cash (Recent Filing)$4.99B
Total Debt (Recent Filing)$14.66B
Price to Earnings (P/E)21.9
Beta0.60
Next Earnings
Feb 05, 2025EPS Estimate
19.8Last Dividend Ex-Date
Nov 14, 2024Dividend Yield4.52%
Share Statistics
EPS (TTM)0.62
Shares Outstanding4,145,133,000
10 Day Avg. Volume7,091,252
30 Day Avg. Volume7,037,733
Standard Deviation0.07
R-Squared0.13
Alpha-0.00350
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.78
Price to Cash Flow (P/CF)13.50
P/FCF Ratio21.00
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue2.32
Enterprise Value/Gross Profit3.41
Enterprise Value/Ebitda8.01
Forecast
1Y Price Target
1,597.78pPrice Target Upside17.57% Upside
Rating ConsensusHold
Number of Analyst Covering11
GlaxoSmithKline News
Bulls Say, Bears Say
Bulls Say
Drug Approval And Market ExpansionThe potential approval and relaunch of Blenrep in the multiple myeloma market could significantly boost GSK's market presence, supported by strong clinical data and manageable side effects.
Legal And Financial StabilityNo more downside risk from Zantac litigation as all cases have been provisioned with a $2.2 billion charge, stabilizing GSK's financial outlook.
Sales Growth And Market PotentialGSK's Cabenuva is expected to generate over £1 billion in sales, with significant growth potential as more patients adopt long-acting treatment regimens.
Bears Say
Competition In HIV TreatmentGilead's novel integrase inhibitors and lenacapavir-based regimens are seen as potentially competitive with GSK's planned regimens.
Research And DevelopmentStarting three major, expensive COPD PIII programs is likely to put material upward pressure on R&D spend and margin compression just as revenues decline on HIV loss of exclusivity.
Vaccine Segment PerformanceArexvy faces challenges due to a narrower US ACIP recommendation for RSV vaccines and wider vaccine fatigue, resulting in modest adoption this season.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.08% Insiders
11.30% Mutual Funds
0.08% Other Institutional Investors
76.46% Public Companies and Individual Investors
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1282.50p and its highest was 1823.50p in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is £55.03B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Feb 05, 2025 which is in 14 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Oct 30, 2024. The company reported 0.497p earnings per share for the quarter, beating the consensus estimate of 0.439p by 0.058p.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Annually dividend of 60.999p which represents an annual dividend yield of 4.52%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 19.8.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,145,133,000 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of 0.497p in its last earnings report, beating expectations of 0.439p. Following the earnings report the stock price went down -3.066%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GB:GSK
---
GlaxoSmithKline Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
1,597.78p (17.57% Upside)
1,597.78p (17.57% Upside)
Insider Transactions
Bought Shares
Worth £99.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.36%
12-Months-Change
Fundamentals
Return on Equity
18.50%
Trailing 12-Months
Asset Growth
-4.62%
Trailing 12-Months
Company Description
GlaxoSmithKline
In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.
---
GSK Stock 12 Month Forecast
Average Price Target
1,597.78p
▲(17.57% Upside)
Technical Analysis
AstraZeneca
―
Hikma Pharmaceuticals
―
Genus plc
―
Futura Medical
―
PureTech Health
―
Alliance Pharma
―
Best Analysts Covering GSK
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+4.18%
reiterated a sell rating last month
Copying Graham Parry's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +4.18% per trade.
---